Polen Capital Management
TSHA icon

Polen Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Polen Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.33M Buy
489,219
+169,471
+53% +$1M 0.03% 84
2026
Q1 		$1.43M Buy
319,748
+163,162
+104% +$759K 0.01% 125
2025
Q4 		$861K Buy
+156,586
New +$760K ﹤0.01% 142

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Polen Capital Management's TSHA Position: Q2 2026 in Review

Polen Capital Management increased its Taysha Gene Therapies (TSHA) stake by 53% in Q2 2026, buying an estimated $1M and bringing the position to 489,219 shares worth $3.33M. The position accounts for 0.03% of the portfolio, ranked #84.

Polen Capital Management first reported a position in TSHA in Q4 2025 and has held it in 3 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Polen Capital Management held 489,219 shares of Taysha Gene Therapies worth $3.33M as of Q2 2026.
  • Polen Capital Management bought 169,471 Taysha Gene Therapies shares in Q2 2026, an estimated $1M.
  • Taysha Gene Therapies made up 0.03% of Polen Capital Management's portfolio in Q2 2026, its #84 holding.
  • Polen Capital Management first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 3 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Polen Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.